Andreas Ohm

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 231(Granted Patents)

Company Filing History:

7 out of 12,160

Bayer Aktiengesellschaft

patents

3 out of 721

Bayer Intellectual Property Gmbh

patents

1 out of 378

Bayer Pharma Aktiengesellschaft

patents

Years Active: 1990-2018

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9993432 - Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic (2018-06-12),

2. 8841446 - Medicaments containing vardenafil hydrochloride trihydrate (2014-09-23),

3. 8273876 - Medicaments containing vardenafil hydrochloride trihydrate (2012-09-25),

4. 8153160 - Pharmaceutical dosage forms comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensin II antagonist (2012-04-10),

5. 6740306 - Imidazotriazinone-containing compositions for nasal administration (2004-05-25),

6. 5900425 - Pharmaceutical preparations having controlled release of active compound (1999-05-04),

7. 5861173 - Long-lasting release nifedipine preparation (1999-01-19),

8. 5204121 - Medicaments having controlled release of the active compound (1993-04-20),

9. 4966772 - DHP delayed release preparation (1990-10-30),

10. 4933186 - Dihydropyridine depot formulation (1990-06-12),

11. 4892741 - Press coated DHP tablets (1990-01-09),

Title: Innovations of Andreas Ohm in Pharmaceutical Patents

Introduction

Andreas Ohm is a distinguished inventor based in Neuss, Germany. With an impressive portfolio of 11 patents, he has made significant contributions to the field of pharmaceuticals. His innovative work focuses on enhancing drug formulations and delivery mechanisms, aiming to improve treatment outcomes for patients.

Latest Patents

Two of his latest patents exemplify his expertise in pharmaceutical innovation. The first patent details a pharmaceutical dosage form comprising nifedipine or nisoldipine combined with an angiotensin II antagonist and/or a diuretic. This invention is characterized by the controlled release of nifedipine or nisoldipine in the body, alongside the rapid release of the angiotensin II antagonist and/or diuretic. It highlights a significant advancement in the treatment of various disorders.

The second patent revolves around medicaments containing vardenafil hydrochloride trihydrate. This patent outlines a method for producing solid form medicaments that contain vardenafil hydrochloride, attesting to Ohm’s focus on effective pharmaceutical production techniques.

Career Highlights

Andreas Ohm has worked with notable institutions, including Bayer Aktiengesellschaft and Bayer Intellectual Property GmbH. His experience in these companies has allowed him to develop a strong foundation in pharmaceutical research and patent development. His contributions have not only advanced scientific knowledge but also have the potential to influence market offerings in the healthcare space.

Collaborations

Throughout his career, Ohm has collaborated with esteemed colleagues such as Helmut Luchtenberg and Manfred Bucheler. These collaborations have fostered a dynamic exchange of ideas and expertise, further enhancing Ohm's innovations.

Conclusion

Andreas Ohm’s work exemplifies the spirit of innovation in the pharmaceutical industry. With a solid number of patents and collaborations with key industry players, he continues to pave the way for advancements in drug delivery and efficacy. His contributions are invaluable for future research and patient care, highlighting the critical role of inventors in the development of effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.